SCHEMBL17808787

SCHEMBL17808787

COCCc1cnc2c(O)c(CN(C)C)ccn2c1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACVR1 Q04771 2/20 0.48
▸ CHEK1 O14757 1/20 0.48
▸ AURKA O14965 1/20 0.48
▸ DAPK3 O43293 1/20 0.48
▸ JAK2 O60674 1/20 0.48
▸ PRKD3 O94806 1/20 0.48
▸ MAP4K4 O95819 1/20 0.48
▸ PAK4 O96013 1/20 0.48
▸ ABL1 P00519 1/20 0.48
▸ NTRK1 P04629 1/20 0.48
▸ LCK P06239 1/20 0.48
▸ FYN P06241 1/20 0.48
▸ CSF1R P07333 1/20 0.48
▸ RET P07949 1/20 0.48
▸ IGF1R P08069 1/20 0.48
▸ MET P08581 1/20 0.48
▸ PDGFRB P09619 1/20 0.48
▸ PIM1 P11309 1/20 0.48
▸ FGFR1 P11362 1/20 0.48
▸ PDGFRA P16234 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17802274 0.87 CHEK1 (0.51) ACVR1CHEK1AURKADAPK3JAK2
SCHEMBL17808792 0.85 CHEK1 (0.49) ACVR1CHEK1AURKADAPK3JAK2
SCHEMBL24344138 0.83 HSD17B10 (0.36) POLBTHRBKDM4EALDH1A1HPGD
SCHEMBL17808907 0.78 CYP2C9 (0.43) CYP2D6POLBKDM4EALDH1A1HPGD
SCHEMBL17808726 0.78 CHEK1 (0.52) ACVR1CHEK1AURKADAPK3JAK2
SCHEMBL19361110 0.77 CHEK1 (0.51) ACVR1CHEK1AURKADAPK3JAK2
SCHEMBL17808853 0.77 KDM4E (0.39) GSK3BRPS6KA3POLBTHRBKDM4E
SCHEMBL17808794 0.76 JAK2 (0.39) ACVR1CHEK1AURKADAPK3JAK2
SCHEMBL17808848 0.75 KDM4E (0.54) ACVR1CHEK1AURKADAPK3JAK2
SCHEMBL19361118 0.75 AURKA (0.36) ACVR1CHEK1AURKADAPK3JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3227292-B1 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS ALTERITY THERAPEUTICS LTD (AU) 2022-03-09 — — EP disclosed
US-20210230159-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2021-07-29 — — US disclosed
US-11008319-B2 4H-pyrido[1,2-a]pyrimidin-4-one compounds PRANA BIOTECHNOLOGY LIMITED (AU) 2021-05-18 — — US disclosed
US-20200317670-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2020-10-08 — — US disclosed
US-10738050-B2 4H-pyrido[1,2-A]pyrimidin-4-one compounds PRANA BIOTECHNOLOGY LIMITED (AU) 2020-08-11 — — US disclosed
US-20190352301-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2019-11-21 — — US disclosed
US-10287285-B2 4H-pyrido[1,2-A]pyrimidin-4-one compounds PRANA BIOTECHNOLOGY LIMITED (AU) 2019-05-14 — — US disclosed
US-20170267676-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2017-09-21 — — US disclosed
US-20170267676-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2017-09-21 — — US disclosed
WO-2016086261-A1 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2016-06-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738050-B2 4H-pyrido[1,2-A]pyrimidin-4-one compounds PSEN2, PSEN1, PNPO ACVR1 4366/4885CHEK1 1474/4885AURKA 996/4885
US-20200317670-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PSEN2, PSEN1, PNPO ACVR1 4366/4885CHEK1 1474/4885AURKA 996/4885
US-10287285-B2 4H-pyrido[1,2-A]pyrimidin-4-one compounds PSEN2, PSEN1, PNPO ACVR1 4366/4885CHEK1 1474/4885AURKA 996/4885
US-11008319-B2 4H-pyrido[1,2-a]pyrimidin-4-one compounds PSEN2, PSEN1, PNPO ACVR1 4366/4885CHEK1 1474/4885AURKA 996/4885
US-20190352301-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PSEN2, PSEN1, PNPO ACVR1 4366/4885CHEK1 1474/4885AURKA 996/4885
US-20210230159-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PSEN2, PSEN1, PNPO ACVR1 4366/4885CHEK1 1474/4885AURKA 996/4885
US-20170267676-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PSEN2, PSEN1, PNPO ACVR1 4366/4885CHEK1 1474/4885AURKA 996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback